ArticleRegenerative biomaterials2025
Injectable hydrogel loaded with exosomes from hypoxic umbilical cord-derived mesenchymal stem cells alleviates intervertebral disc degeneration by reversing nucleus pulposus cell senescence.
Article in Regenerative biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Biomaterials for intervertebral disc regeneration: Niche reprogramming, precision therapeutics, and structural reconstruction.Bioactive materials · 2027Review
- Precision mitochondrial delivery for tissue repair in intervertebral disc degeneration.Journal of nanobiotechnology · 2026Article
- Exosome-based therapies for corneal disorders: current status and future perspectives.MedScience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intervertebral disc degeneration is a significant contributor to the development of spinal disorders. Previous studies have shown that the senescence of nucleus pulposus cells can worsen the degradation of intervertebral disks. Therefore, targeting the senescence of nucleus pulposus cells may be a promising therapeutic approach for the treatment of intervertebral disc degeneration. This study investigated the use of exosomes from hypoxic umbilical cord-derived mesenchymal stem cells to reverse nucleus pulposus cells senescence and delay intervertebral disc degeneration progression. MicroRNA sequencing of hypoxic umbilical cord-derived mesenchymal stem cells revealed the presence of functional microRNAs, with the p53 signalling pathway identified as a key factor. To enhance the release time of hypoxic umbilical cord-derived mesenchymal stem cells
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.